The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria Spector SL, Shikiar R, Harding G, Meeves S, Leahy MJ.
The present study examined the impact of once-daily fexofenadine hydrochloride (HCl) 180 mg on health-related quality of life (HRQL) in subjects with chronic idiopathic urticaria (CIU). This was a multicenter, randomized, double-blind. parallel-group, placebo-controlled study. Subjects completed the Dermatology Life Quality Index (DLQI) and the Work Productivity and Activity Impairment (WPAI) questionnaire at baseline and at weeks 2 and 4. The primary HRQL end point was mean change from baseline to week 4 in total DLQI score. Subjects in the fexofenadine HCl treatment group (n = 163) experienced significantly greater improvements in mean total DLQI score (P = .0219) and in the individual domains of symptoms and feelings (P = .0119) and personal relationships (P = .0091) compared with those in the placebo group (n = 91). Subjects who received fexofenadine HCl experienced less work productivity impairment, overall work impairment, and activity impairment than those who received placebo. The results indicated that once-daily fexofenadine HCl 180 mg improved the HRQL of subjects with CIU, as assessed by change in total DLQI score.
Spector, S. L., Shikiar, R., Harding, G., Meeves, S., & Leahy, M. (2007). The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria: Spector SL, Shikiar R, Harding G, Meeves S, Leahy MJ. Cutis, 79(2), 157-62.